Potentials and Pitfalls of Clinical Peptidomics and Metabolomics
News Jul 08, 2013
Clinical peptidomics and metabolomics are two emerging "-omics" technologies with the potential not only to detect disease-specific markers, but also to give insight into the disease dependency of degradation processes and metabolic pathway alterations. However, despite their rapid evolution and major investments, a clinical breakthrough, such as the approval of a major cancer biomarker, is still out of sight. What are the reasons for this failure? In this review we focus on three important factors: sensitivity, specificity and the avoidance of bias. The way to clinical implementation of peptidomics and metabolomics is still hampered by many of the problems that had to be solved for genomics and proteomics in the past, as well as new ones that require the creation of new analytic, computational and interpretative techniques. The greatest challenge, however, will be the integration of information from different "-omics" subdisciplines into straightforward answers to clinical questions, for example, in the form of new, superior "meta-markers".
The article is published online in Swiss Medical Weekly and is free to access.
Menopause and Estrogen Affect Muscle FunctionNews
By applying a proteomics approach to investigate the protein content of the muscle and taking into account the participants’ age, menopausal status and the use of estrogen-containing hormonal therapy, researchers were able to identify proteins associated with skeletal muscle ageing.READ MORE